ライフサイエンスコーパス: tumor recurrence

1 asymmetric cell division and responsible for tumor recurrence.

2 sion and inability to adequately monitor for tumor recurrence.

3 ape of tumor cells that survive and initiate tumor recurrence.

4 ironment contributing to drug resistance and tumor recurrence.

5 s, which was associated with increased local tumor recurrence.

6 tered gene expression may be associated with tumor recurrence.

7 Ipsilateral breast tumor recurrence.

8 le duct strictures, incomplete ablation, and tumor recurrence.

9 oves ITT-OS, and it is not a risk factor for tumor recurrence.

10 aneous treatment more effectively suppressed tumor recurrence.

11 (MR) imaging was used to evaluate for local tumor recurrence.

12 city required for metastatic progression and tumor recurrence.

13 ammary cell population expansion, attenuated tumor recurrence.

14 ere used to quantify associations with local tumor recurrence.

15 ion of patients in relation to their risk of tumor recurrence.

16 without any histologic or clinical signs of tumor recurrence.

17 ho showed complete resolution, 4 experienced tumor recurrence.

18 1 in meningioma as a marker that can predict tumor recurrence.

19 ow-up (67 and 47 months) revealed no sign of tumor recurrence.

20 in 5 years of surgery, and 235 (39%) died of tumor recurrence.

21 been correlated to increased metastasis and tumor recurrence.

22 r growth, contribute to resistance and drive tumor recurrence.

23 d increased overall, locoregional, and mixed tumor recurrence.

24 er methylation status remained prognostic at tumor recurrence.

25 in glioblastoma (GBM) are often conducted at tumor recurrence.

26 t vs none; P = .05) were associated with HCC tumor recurrence.

27 roportionately to therapeutic resistance and tumor recurrence.

28 om a surgical approach and suffer from early tumor recurrence.

29 association of race and genetic traits with tumor recurrence.

30 and significance of the racial disparity in tumor recurrence.

31 es effective treatment and virtually assures tumor recurrence.

32 h virus infection, tumor size, cirrhosis and tumor recurrence.

33 functions and a low rate of reoperation for tumor recurrence.

34 mor propagation, therapeutic resistance, and tumor recurrence.

35 sociated with a significant 25% reduction in tumor recurrence.

36 effect on stem cells that may contribute to tumor recurrence.

37 s a microenvironment that fosters aggressive tumor recurrence.

38 apeutics with anti-inflammatories may reduce tumor recurrence.

39 tumor regression and successfully prevented tumor recurrence.

40 ility, enhanced tumor resection, and reduced tumor recurrence.

41 zard ratio = 3.0; 95% CI: 1.3, 7.2; P = .01) tumor recurrence.

42 ciated with clinical disease progression and tumor recurrence.

43 er therapeutics to CD133+ cells for reducing tumor recurrence.

44 the effect of the mutations on survival and tumor recurrence.

45 ndent state, delaying or completely blocking tumor recurrence.

46 ffects from radiation, metastasis, and local tumor recurrence.

47 but many treated patients relapse with local tumor recurrence.

48 gression of advanced disease was followed by tumor recurrence.

49 onse and cell cycle gene expression in colon tumor recurrence.

50 it correlates with poor therapy response and tumor recurrence.

51 PPV, BCVA was 20/20 and there was no sign of tumor recurrence.

52 ns is essential for an accurate diagnosis of tumor recurrence.

53 and provided long-lasting protection against tumor recurrence.

54 pic heterogeneity drives drug resistance and tumor recurrence.

55 onally different populations of GBM cells in tumor recurrence.

56 nd DAXX-stabilizing agents may inhibit ER(+) tumor recurrence.

57 into normal brain tissue are responsible for tumor recurrence.

58 es recommend a "wait-and-watch" approach for tumor recurrence.

59 n non-HCC recipients, most likely because of tumor recurrence.

60 of approximately 60%, notwithstanding early tumor recurrence.

61 ma cells and significantly prolonged time to tumor recurrence.

62 esents a significant challenge in preventing tumor recurrence.

63 receiving LT) for HCC are at a high risk for tumor recurrence.

64 ery may eliminate micrometastases and reduce tumor recurrence.

65 ajor TIC subtypes simultaneously and inhibit tumor recurrence.

66 y response that promotes dormancy escape and tumor recurrence.

67 derlying the bladder cancer field effect and tumor recurrence.

68 r microenvironment as critical for promoting tumor recurrence.

69 e zones of sublethal injury that may promote tumor recurrence.

70 ition to gemcitabine chemotherapy to prevent tumor recurrence.

71 melanoma, substantially reducing the risk of tumor recurrences.

72 specific pretransplant locations, suggesting tumor recurrences.

73 atients with isolated ipsilateral chest wall tumor recurrences (2 of 67; crude rate, 3%).

74 All histopathologically confirmed tumor recurrences (3 of 55 orbits, 5.5%) were correctly

75 gorized in 4 groups: PET/CT for diagnosis of tumor recurrence (303/1,659, 18.3%), PET/CT before start

76 9 months, standard deviation = 55), 16 local tumor recurrences (5.1%) were detected.

77 3.9%), PET/CT to assess therapy response for tumor recurrence (507/1,659, 30.6%), and follow-up PET/C

78 , 18.3%), PET/CT before starting therapy for tumor recurrence (64/1,659, 3.9%), PET/CT to assess ther

79 -up PET/CT after completion of treatment for tumor recurrence (785/1,659, 47.3%).

80 ALN status was not associated with tumor recurrence [adjusted hazard ratio (HR) 1.02, 95% c

81 airs tumor initiation, and increases time to tumor recurrence after chemotherapy is discontinued.

82 nance therapy between MTD cycles and prevent tumor recurrence after completing remission for certain

83 atoid subtype is an independent predictor of tumor recurrence after curative treatment and all-cause

84 The prevention of tumor recurrence after curative treatment of hepatocellu

85 ore may be a useful tool to evaluate orbital tumor recurrence after enucleation in children with reti

86 Sixty-three patients (57%) had tumor recurrence after initial resection, and in 30 pati

87 ttributed to metastatic spread of disease or tumor recurrence after initial treatment.

88 p explain the phenomenon of aggressive local tumor recurrence after liver surgery and offer a potenti

89 The aim of this study was to investigate tumor recurrence after liver transplantation for hepatoc

90 Results The rate of tumor recurrence after liver transplantation was 11.5% (

91 vessel invasion of HCC cells, higher risk of tumor recurrence after liver transplantation, strong pho

92 o tumor biology and has predictive value for tumor recurrence after liver transplantation.

93 8)F-FDG PET/CT might be able to detect local tumor recurrence after nCRT as soon as the esophagus rec

94 r-cell renal-cell carcinoma at high risk for tumor recurrence after nephrectomy, the median duration

95 gional renal-cell carcinoma at high risk for tumor recurrence after nephrectomy.

96 llar sclerectomy (13% vs. 8%; P = 0.29), and tumor recurrence after primary treatment (30% vs. 20%; P

97 high-risk tumor features and higher rates of tumor recurrence after primary TTT of (small) choroidal

98 evaluated biometrics for prediction of local tumor recurrence after renal cell carcinoma ablation.

99 However, tumor recurrence after resection, the mechanisms of whic

100 immunity can effectively reduce the risk of tumor recurrence after surgery, facilitating long-term r

101 This system also prevents tumor recurrence after surgical resection and results in

102 to develop and validate a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score for pa

103 a novel prognostic index, Risk Estimation of Tumor Recurrence After Transplant (RETREAT), which incor

104 lastoma, antigen escape variants can lead to tumor recurrence after treatment with CAR T cells that a

105 extraocular tumor extension was intraocular tumor recurrence after TTT treated with additional TTT (

106 In summary, our work shows how tumor recurrences after long-term latency evolve toward

107 Tumor recurrence also has a negative effect on posttrans

108 went enucleation because of a presumed local tumor recurrence and 4 additional patients underwent enu

109 Inevitable tumor recurrence and a poor median survival are frustrat

110 Subsequent PDT further reduced tumor recurrence and extended animal survival significan

111 ociated with low rates of ipsilateral breast tumor recurrence and has the potential to decrease re-ex

112 ons with oxaliplatin-has reduced the risk of tumor recurrence and improved survival for patients with

113 supported chemotherapy and suppressed local tumor recurrence and improved survival involving both NK

114 reast cancer significantly reduces in-breast tumor recurrence and improves overall survival.

115 mory response that protects mice from future tumor recurrence and increases sensitivity to PD-L1 bloc

116 ells play a major role in protection against tumor recurrence and infection after allogeneic hematopo

117 toward type 2 immunity, may predict bladder tumor recurrence and influence the mortality of patients

118 hyma over a long period of time, suppressing tumor recurrence and leading to prolonged survival.

119 Conclusion LRT significantly decreased tumor recurrence and lengthened overall survival.

120 were completed to evaluate risk factors for tumor recurrence and melanoma-related mortality.

121 ntities for initial staging and detection of tumor recurrence and metastases, including peritonitis c

122 anticancer therapies, which may account for tumor recurrence and metastasis by regenerating new tumo

123 entified miR-139-5p as a novel biomarker for tumor recurrence and metastasis in CRC.

124 oited to potentiate immunotherapy and reduce tumor recurrence and metastasis.

125 survival of residual cancer cells to foster tumor recurrence and metastasis.

126 tem cells (BCSCs), which are responsible for tumor recurrence and metastasis.

127 and been considered as the driving force of tumor recurrence and metastasis.

128 ncer metastasis, which is the major cause of tumor recurrence and mortality.

129 lished reporting markedly increased rates of tumor recurrence and occurrence after viral clearance wi

130 brain parenchyma, which invariably leads to tumor recurrence and patient death.

131 is known to be an important risk factor for tumor recurrence and patient mortality.

132 single-institution series have demonstrated tumor recurrence and patient survival rates that approxi

133 PNI represents a major determinant of tumor recurrence and patients' survival in pancreatic ca

134 s strongly correlated with decreased time to tumor recurrence and poor patient survival.

135 Importantly, the increased tumor recurrence and progression in human patients with

136 ells that are proposed to be responsible for tumor recurrence and relapse.

137 f glioma stem cells, the cells implicated in tumor recurrence and resistance to therapy in patients w

138 ow report that Par-4 is downregulated during tumor recurrence and that Par-4 downregulation is necess

139 ession, with implications for how to prevent tumor recurrence and the establishment of metastatic les

140 metastatic lesions and rationalizations for tumor recurrence and therapeutic failures.

141 ge to assess complete ablation, intrahepatic tumor recurrence, and complications.

142 block copolymer on the therapeutic efficacy, tumor recurrence, and development of drug resistance was

143 s of visual acuity retention, eye retention, tumor recurrence, and melanoma-related mortality were ca

144 lete tumor removal, increases the chances of tumor recurrence, and necessitates costly repeat surgery

145 therapy on posttransplant patient survival, tumor recurrence, and patient survival without transplan

146 have been associated with cancer metastasis, tumor recurrence, and poor outcomes.

147 enhances the effect of temozolomide, delays tumor recurrence, and prolongs survival.

148 at activation of Notch signaling accelerates tumor recurrence, and that inhibition of Notch signaling

149 Seventeen (77.2%) patients died of tumor recurrence, and the remaining 5 patients died of e

150 ug resistance; thus it can drive metastasis, tumor recurrence, and therapy resistance in the context

151 ostsurgical contrast enhancement and orbital tumor recurrence, and therefore may be a useful tool to

152 emoradiation, resulting in a typically fatal tumor recurrence approximately 7 mo after diagnosis.

153 ative surgery is followed at a later date by tumor recurrence as a consequence of circulating tumor c

154 (18)F-AH113804 PET detected local tumor recurrence as early as 6 d after surgery in the re

155 thout (184 regions) local contrast-enhancing tumor recurrence at follow-up MR imaging (median, 7.3 mo

156 opsy were described in 15.9% (n = 7), but no tumor recurrence at the sclerotomy sites was observed.

157 a Immunoscore provides a potent indicator of tumor recurrence beyond microsatellite-instability stagi

158 ongly associated with therapy resistance and tumor recurrence, but the underlying mechanisms are inco

159 cape of antigen loss variants and subsequent tumor recurrence by enabling T cells to eliminate cancer

160 CCL5 promotes tumor recurrence by recruiting CCR5-expressing macrophag

161 th SHH-subgroup MB, in order to decrease the tumor recurrence commonly observed in patients treated w

162 icantly reduced the tumor burden and delayed tumor recurrence compared to Taxol treatment alone.

163 the patients who had an N+ status developed tumor recurrences compared with 5.2% of those who had no

164 Patients within cluster 2 showed earlier tumor recurrence, compared with those within cluster 1 (

165 hesized to evade current therapies and cause tumor recurrence, contributing to poor patient survival.

166 Tumor recurrence correlated with the number of high-risk

167 last follow-up, and none of 2 patients with tumor recurrence developed metastases in the transplanta

168 Rates of necrosis and tumor recurrence did not differ between groups.

169 PET/CT might be a useful tool for detecting tumor recurrence during active surveillance.

170 is limited knowledge regarding its impact on tumor recurrence, especially in "early stage disease" (P

171 t in children with retinoblastoma to exclude tumor recurrence, especially in high-risk patients withi

172 most SCID mice eventually succumbed to local tumor recurrence even with combined cryoablation and CpG

173 d be used first in patients at high risk for tumor recurrence, followed by screening high-risk popula

174 lastoma that may be a cellular reservoir for tumor recurrence following cytotoxic therapy.

175 ramide kinase (Cerk) is required for mammary tumor recurrence following HER2/neu pathway inhibition a

176 initiating cells (GICs), which contribute to tumor recurrence following initial response to therapy.

177 ombination of dasatinib and rapamycin delays tumor recurrence following the cessation of treatment.

178 Tumor recurrence following treatment is the major cause

179 Tumor recurrence following treatment remains a major cli

180 Tumor recurrence following treatment remains a major cli

181 on of the tumor is critical to the patient's tumor recurrence-free survival.

182 , these results implicate Notch signaling in tumor recurrence from dormant residual tumor cells and p

183 Klatskin tumor patients with a history of tumor recurrence had significantly higher MACC1 expressi

184 Five of 24 patients with tumor recurrence had sudden intense SUL(max) increases o

185 cluding resistance to current treatments and tumor recurrence, has been attributed to glioma stemlike

186 To this end, tumor recurrences have been attributed to the presence o

187 strong, independent, prognostic indicator of tumor recurrence (hazard ratio, 5.063; 95% confidence in

188 additional adjuvant treatments and minimize tumor recurrence; however, there is a delicate balance b

189 e interval [CI], 3.12-13.43; P < 0.0001) and tumor recurrence (HR, 4.08; 95% CI, 1.72-9.66; P = 0.001

190 al (HR, 8.336; 2.734-25.418; P < 0.001), and tumor recurrence (HR, 8.031; 3.041-21.206; P < 0.001) th

191 e cumulative incidence of ipsilateral breast tumor recurrence (IBTR) as a first event within 10 years

192 Time to ipsilateral breast tumor recurrence (IBTR) as first event.

193 the 5-year difference in ipsilateral breast tumor recurrence (IBTR) between 30 Gy in 5 once-daily fr

194 lysis of margin width and ipsilateral breast tumor recurrence (IBTR) from a systematic review of 20 s

195 lysis of margin width and ipsilateral breast tumor recurrence (IBTR) from a systematic review of 33 s

196 ct of postoperative RT on ipsilateral breast tumor recurrence (IBTR) in a large randomized trial.

197 To compare ipsilateral breast tumor recurrence (IBTR) in women with DCIS treated with

198 Prognostic factors of ipsilateral breast tumor recurrence (IBTR) may change over time following b

199 %) showed pathologic findings indicative for tumor recurrence in (68)Ga-PSMA ligand PET/CT.

200 Indications for secondary enucleation were tumor recurrence in 60 (61%), neovascular glaucoma in 21

201 ially represent an early detection marker of tumor recurrence in a subset of patients treated with TM

202 tumors to HER2-targeted therapies and delay tumor recurrence in a transgenic model of HER2-positive

203 and ROS as therapeutic targets for reducing tumor recurrence in breast cancer patients.

204 acy of high-resolution MRI to detect orbital tumor recurrence in children with retinoblastoma in a la

205 nation of PF-562271 and cabozantinib delayed tumor recurrence in contrast to cabozantinib treatment a

206 rapy and DAXX-stabilizing agents may inhibit tumor recurrence in ER(+) breast cancer.

207 Tumor recurrence in glioblastoma (GBM) is, in part, attr

208 NEPTRs) at baseline is associated with later tumor recurrence in glioblastoma.

209 ells were enriched by chemotherapy and drove tumor recurrence in glioblastoma.

210 a mechanism for driving chemoresistance and tumor recurrence in human cancers including triple negat

211 tion and is spontaneously upregulated during tumor recurrence in multiple genetically engineered mous

212 tivities might be used to reduce the risk of tumor recurrence in patients undergoing colorectal cance

213 her tumor biometrics for prediction of local tumor recurrence in patients with renal cell carcinoma a

214 The diagnosis of tumor recurrence in rhabdomyosarcoma is extremely challe

215 Kaplan-Meier estimates for tumor recurrence in the 1995 to 2000 group were 29% at 5

216 s and 42% at 10 years, whereas estimates for tumor recurrence in the 2001-2012 group were 11% at 5 ye

217 ared to only 5.7% (n = 4/70) recipients with tumor recurrence in the HOPE-treated DCD cohort (P = 0.0

218 Conclusion Local tumor recurrence in the NEPTR may be predicted by FA met

219 s an independent predictor for mortality and tumor recurrence in the propensity model (hazard ratio,

220 esulted in a higher detection rate for local tumor recurrence in the prostatic bed in men with bioche

221 the frequency of CT scans with the hazard of tumor recurrence in time.

222 identified patients at high or low risk for tumor recurrence in two independent patient cohorts.

223 barcoding to monitor clonal dynamics during tumor recurrence in vivo.

224 echanisms by which the Western diet promotes tumor recurrence, including changes in the microbiome, i

225 stal pancreatectomies, and 10 resections for tumor recurrences, including 121 multivisceral resection

226 Furthermore, local tumor recurrence increased the risk of metastasis by a h

227 priately timed, highly targeted treatment of tumor recurrence irrespective of tumor type or frontline

228 distinguishing post-treatment changes from a tumor recurrence is a challenge due to the anatomical al

229 Tumor recurrence is a leading cause of cancer mortality.

230 Orbital tumor recurrence is a rare but serious complication in c

231 y for localized, primary GIST, postoperative tumor recurrence is common.

232 treatment regimens centered on radiotherapy, tumor recurrence is inevitable and is thought to be driv

233 bitors (BRAFi), but responses are varied and tumor recurrence is inevitable.

234 cial in their follow-up, especially when the tumor recurrence is not clinically evident.

235 Tumor recurrence is the leading cause of breast cancer-r

236 in low-grade gliomas (LGGs), but its role in tumor recurrence is unclear.

237 lantation was considered upon development of tumor recurrence/liver function impairment.

238 Local tumor recurrence (LR) developed in 4 of 41 tumors (9.8%)

239 the long-term, 7 (16.7%) patients had local tumor recurrence (managed with repeat NSS in 6 and compl

240 ression levels are associated with increased tumor recurrence, metastatic foci, and reduced disease-f

241 tumor recurrence (n = 55 eyes, 44%), eyelid tumor recurrence (n = 5 eyes, 31%), locoregional lymph n

242 There were events of ocular surface tumor recurrence (n = 55 eyes, 44%), eyelid tumor recurr

243 condary enucleations for uveal melanoma were tumor recurrence, neovascular glaucoma, and tumor nonres

244 ly account for some of the local and distant tumor recurrence observed after treatment.

245 Tumor recurrence occurs in almost 10% after liver transp

246 istance to these therapies leads to systemic tumor recurrence of metastatic disease.

247 ing was used to evaluate the effect of local tumor recurrence on metastatic rate.

248 resistance, and may serve as reservoirs for tumor recurrence on reoxygenation.

249 ontinuing immunotherapy may result in either tumor recurrence or a durably sustained response.

250 o curative resection subsequently experience tumor recurrence or metastasis.

251 ET/CT (=PET) improves the detection of local tumor recurrence or of nodal and distant metastases in p

252 l aberrations, including all 3 patients with tumor recurrence or progression.

253 t radiotherapy of brain tumors could promote tumor recurrence or trigger secondary gliomas.

254 y higher MACC1 expression than those without tumor recurrence (P = 0.005).

255 inical outcome than fenestration in terms of tumor recurrence (p = 0.018).

256 ence of orange pigment before TTT (P=0.019), tumor recurrence (P=0.002), and extraocular tumor extens

257 gh GPx2 expression was associated with early tumor recurrence, particularly in the recently identifie

258 s evaluated included surgical complications, tumor recurrence, patient survival, and renal function,

259 esected and mice were given gemcitabine, and tumor recurrence patterns and survival were determined.

260 nique, implantation tumor development, local tumor recurrence, presence of metastatic disease after s

261 Adaptive chemoresistance and consequent tumor recurrence present major obstacles to the improvem

262 ecially with I-CCA features, showed a 5-year tumor recurrence rate (10%) and 5-year survival rate (78

263 The overall 5-year tumor recurrence rate (95% confidence interval) was 3.3%

264 ence in tumor load, we found a 4-fold higher tumor recurrence rate in unperfused DBD livers (25.7%, 1

265 The tumor recurrence rate was also twice higher in unperfuse

266 Tumor recurrence rates at 1, 3, and 5 years were 2.4%, 6

267 Tumor recurrence rates were 25.8% (50 of 194;77.60 recur

268 Tumor recurrence rates were low and mortality rates were

269 etransplant tumor are at significant risk of tumor recurrence, regardless of the length of interval b

270 Tumor recurrence remains the main reason for breast canc

271 rm survivorship, treatment failure and rapid tumor recurrence remains universal.

272 4 cases showed further distant conjunctival tumor recurrence remote from the site of radiotherapy wi

273 ncer cell plasticity promotes metastasis and tumor recurrence, resulting in patient mortality.

274 posure to vismodegib is necessary to prevent tumor recurrence, suggesting the existence of a vismodeg

275 patient-detrimental desmoplasia and foretell tumor recurrences, suggesting a useful new prognostic to

276 In 19 of 24 patients with tumor recurrence, SUL(max) gradually increased (median D

277 tion need to be balanced against the risk of tumor recurrence, taking into consideration the potentia

278 re significantly lower in regions with later tumor recurrence than in regions without (median FAcontr

279 , PET/mpMR was more often positive for local tumor recurrence than PET (P = 0.039) or mpMR (P = 0.019

280 African Americans had a higher risk of tumor recurrence than whites (hazard ratio, 2.22; 95% CI

281 tory T cells (Tregs) alone failed to reverse tumor recurrence, the combination of PD-L1 blockade with

282 otherapy-induced TGF-beta signaling enhances tumor recurrence through IL-8-dependent expansion of CSC

283 e analyzed for ITT-OS using a Cox model; and tumor recurrence using 2 competitive risk models.

284 gene or pathway calculation of trial size at tumor recurrence, using molecular data of the primary tu

285 chemotherapy-treated patients who experience tumor recurrence vs. no recurrence.

286 ession and various tumor features as well as tumor recurrence was analyzed.

287 In that local tumor recurrence was associated with a significantly hig

288 Tumor recurrence was defined as biopsy-proven vital tumo

289 Local tumor recurrence was detected in 20 of 76 (26.3%) on (18

290 In patients outside UCSF, tumor recurrence was equivalent to Milan and UCSF criter

291 Tumor recurrence was histology confirmed in 40% (28/70)

292 Tumor recurrence was histology-confirmed in 40% (28/70)

293 Although tumor recurrence was more likely in outside of UCSF pati

294 f 40 completely ablated tumors, intrahepatic tumor recurrence was observed at 2-18 months.

295 Tumor recurrence was significantly less common in pN0 pa

296 -up MRI exam 32 months after the operation a tumor recurrence was suggested.

297 pecificity of MR imaging in the detection of tumor recurrence were 100% (six of six patients) and 52%

298 ultivariate analysis, features predictive of tumor recurrence were presence of symptoms (P<0.001), sh

299 sively into distant brain tissue, leading to tumor recurrence, which is ultimately incurable.

300 of 115 prostatectomy patients with suspected tumor recurrence who underwent both (11)C-choline PET/CT